AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AMRX • US03168L1052

14.77 USD
+0.34 (+2.36%)
At close: Feb 5, 2026
14.64 USD
-0.13 (-0.88%)
After Hours: 2/5/2026, 8:09:16 PM
Fundamental Rating

5

Overall AMRX gets a fundamental rating of 5 out of 10. We evaluated AMRX against 191 industry peers in the Pharmaceuticals industry. AMRX has only an average score on both its financial health and profitability. AMRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • AMRX had positive earnings in the past year.
  • AMRX had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: AMRX reported negative net income in multiple years.
  • Each year in the past 5 years AMRX had a positive operating cash flow.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.16%, AMRX is in the better half of the industry, outperforming 77.49% of the companies in the same industry.
  • AMRX has a Return On Invested Capital of 10.43%. This is amongst the best in the industry. AMRX outperforms 90.05% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AMRX is below the industry average of 12.87%.
  • The last Return On Invested Capital (10.43%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.16%
ROE N/A
ROIC 10.43%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

  • AMRX has a better Profit Margin (0.20%) than 77.49% of its industry peers.
  • AMRX has a Operating Margin of 12.32%. This is amongst the best in the industry. AMRX outperforms 85.34% of its industry peers.
  • In the last couple of years the Operating Margin of AMRX has grown nicely.
  • AMRX's Gross Margin of 36.76% is fine compared to the rest of the industry. AMRX outperforms 60.21% of its industry peers.
  • AMRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 12.32%
PM (TTM) 0.2%
GM 36.76%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AMRX is destroying value.
  • AMRX has less shares outstanding than it did 1 year ago.
  • AMRX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for AMRX has been reduced compared to a year ago.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 2.00 indicates that AMRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • AMRX's Altman-Z score of 2.00 is fine compared to the rest of the industry. AMRX outperforms 60.21% of its industry peers.
  • The Debt to FCF ratio of AMRX is 11.13, which is on the high side as it means it would take AMRX, 11.13 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of AMRX (11.13) is better than 78.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.13
Altman-Z 2
ROIC/WACC1
WACC10.44%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • AMRX has a Current Ratio of 2.13. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
  • AMRX's Current ratio of 2.13 is on the low side compared to the rest of the industry. AMRX is outperformed by 60.21% of its industry peers.
  • AMRX has a Quick Ratio of 1.42. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.42, AMRX is doing worse than 65.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.42
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.00% over the past year.
  • The Earnings Per Share has been growing by 10.63% on average over the past years. This is quite good.
  • The Revenue has grown by 16.73% in the past year. This is quite good.
  • Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 11.43% on average per year.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.95% on average over the next years. This is quite good.
  • Based on estimates for the next years, AMRX will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y40.2%
EPS Next 2Y28.34%
EPS Next 3Y26.83%
EPS Next 5Y11.95%
Revenue Next Year8.74%
Revenue Next 2Y7.6%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 19.69, which indicates a rather expensive current valuation of AMRX.
  • Based on the Price/Earnings ratio, AMRX is valued cheaply inside the industry as 82.20% of the companies are valued more expensively.
  • AMRX is valuated rather cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 15.46, which indicates a correct valuation of AMRX.
  • AMRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 82.20% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AMRX to the average of the S&P500 Index (27.20), we can say AMRX is valued slightly cheaper.
Industry RankSector Rank
PE 19.69
Fwd PE 15.46
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaply inside the industry as 86.39% of the companies are valued more expensively.
  • AMRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMRX is cheaper than 85.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF 19.63
EV/EBITDA 11.75
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of AMRX may justify a higher PE ratio.
  • A more expensive valuation may be justified as AMRX's earnings are expected to grow with 26.83% in the coming years.
PEG (NY)0.49
PEG (5Y)1.85
EPS Next 2Y28.34%
EPS Next 3Y26.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (2/5/2026, 8:09:16 PM)

After market: 14.64 -0.13 (-0.88%)

14.77

+0.34 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30
Earnings (Next)02-27
Inst Owners45.17%
Inst Owner Change-0.16%
Ins Owners46.29%
Ins Owner Change-4.23%
Market Cap4.64B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts81.82
Price Target14.79 (0.14%)
Short Float %4.34%
Short Ratio2.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)3.57%
PT rev (3m)20.83%
EPS NQ rev (1m)-1.1%
EPS NQ rev (3m)1.75%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)3.53%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 19.69
Fwd PE 15.46
P/S 1.58
P/FCF 19.63
P/OCF 14.17
P/B N/A
P/tB N/A
EV/EBITDA 11.75
EPS(TTM)0.75
EY5.08%
EPS(NY)0.96
Fwd EY6.47%
FCF(TTM)0.75
FCFY5.09%
OCF(TTM)1.04
OCFY7.06%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.49
PEG (5Y)1.85
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.16%
ROE N/A
ROCE 13.2%
ROIC 10.43%
ROICexc 11.26%
ROICexgc 21.11%
OM 12.32%
PM (TTM) 0.2%
GM 36.76%
FCFM 8.06%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.13
Debt/EBITDA 4.36
Cap/Depr 37.95%
Cap/Sales 3.11%
Interest Coverage 1.67
Cash Conversion 54.45%
Profit Quality 4008.53%
Current Ratio 2.13
Quick Ratio 1.42
Altman-Z 2
F-Score7
WACC10.44%
ROIC/WACC1
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.2%
EPS Next 2Y28.34%
EPS Next 3Y26.83%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.74%
Revenue Next 2Y7.6%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.18%
EBIT Next 3Y10.07%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%

AMNEAL PHARMACEUTICALS INC / AMRX FAQ

What is the fundamental rating for AMRX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AMRX.


What is the valuation status for AMRX stock?

ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.


How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?

AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.


How financially healthy is AMNEAL PHARMACEUTICALS INC?

The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.


Can you provide the expected EPS growth for AMRX stock?

The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.2% in the next year.